Brilinta is the brand name for ticagrelor [1]. It is a medication used to prevent thrombotic events, such as heart attack or stroke, in patients with acute coronary syndrome [2].
Why is Brilinta prescribed?
Brilinta is prescribed for individuals who have experienced a recent heart attack or have been diagnosed with unstable angina [2]. It helps to reduce the risk of these serious cardiovascular events by inhibiting platelet aggregation [2].
How does ticagrelor work?
Ticagrelor is a P2Y12 platelet inhibitor. It works by reversibly binding to the P2Y12 receptor on platelets, preventing adenosine diphosphate (ADP) from activating them [2]. This action reduces the ability of platelets to clump together and form blood clots [2].
When does Brilinta's patent expire?
The patent protection for Brilinta varies by region and patent type. For instance, the primary U.S. patent for ticagrelor expired in 2020 [3]. However, other patents related to formulations or methods of use may have later expiration dates [3]. Information on specific patent expirations can be found at DrugPatentWatch.com [3].
Are there generic versions of ticagrelor available?
With the expiration of primary patents, generic versions of ticagrelor are becoming available [3]. The introduction of generics can lead to increased competition and potentially lower prices for the medication.
What are the risks associated with Brilinta?
Like all medications, Brilinta carries potential risks and side effects. Common side effects include bleeding (such as bruising or nosebleeds), shortness of breath, and diarrhea [2]. More serious risks include severe bleeding events and a slowing of heart rate (bradycardia) [2]. Patients should discuss their medical history and any concerns with their healthcare provider before starting this medication.
How does Brilinta compare to other antiplatelet drugs?
Brilinta belongs to a class of drugs known as P2Y12 inhibitors, which also includes clopidogrel (Plavix) and prasugrel (Effient) [4]. While all aim to prevent blood clots, they differ in their mechanism of action, potency, and bleeding risk profiles [4]. Ticagrelor is a reversible inhibitor, meaning its effect can be undone more easily than some other P2Y12 inhibitors [2, 4]. Clinical studies have compared these agents to guide treatment decisions based on individual patient characteristics and risk factors [4].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.nhs.uk/medicines/ticagrelor/
[3] https://www.drugpatentwatch.com/blog/ticagrelor-patent-expiry
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763942/